WaveMan
WaveMan · Company
AURA · Aura Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AURA Aura Biosciences (AURA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001501796
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
94
13F, latest reported quarter

What the filings say about AURA

Insiders, 180 days
-$39.1M net sold
2 sellers · 0% of sales under a 10b5-1 plan

Aura Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aura Biosciences, Inc. insiders sold a net $39.1M of stock across 63 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gibney Anthony S
See Remarks
SELL
2026-06-16 SEC
12,824
$82.3K
-0.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on May 16, 2025.
  • The trade is 4.8% of the 265,354 shares held after it.
  • No other insider sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Gibney Anthony S sold about $82.3K of AURA on Jun 16, 2026; 94 funds added in the latest 13F quarter.
Matrix Capital Management Company, LP
SELL
2026-05-11 SECtraded 2026-05-07
6,922,870
$39.0M
-20.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 9, 2023.
  • +0.6% median (+0.6% mean) 90-day return after 2 previous buys.
  • 1 other insider sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Matrix Capital Management Company, LP sold about $39.0M of AURA on May 7, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.
Kilroy Conor
See Remarks
SELL
2026-04-16 SEC
11,738
$82.4K
-13.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 17, 2026.
  • The trade is 5.4% of the 217,835 shares held after it.
  • 1 other insider sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Kilroy Conor sold about $82.4K of AURA on Apr 16, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.
Kilroy Conor
See Remarks
SELL
2026-02-17 SEC
12,079
$61.0K
+25.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 16, 2025.
  • The trade is 7.2% of the 167,234 shares held after it.
  • 4 other insiders sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Kilroy Conor sold about $61.0K of AURA on Feb 17, 2026; 4 other insiders sold within 30 days and 94 funds added in the latest 13F quarter.
Plavsic Mark
Chief Technology Officer
SELL
2026-02-17 SEC
15,890
$80.2K
+25.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Oct 16, 2025.
  • The trade is 8.8% of the 181,397 shares held after it.
  • 4 other insiders sold within 30 days.
  • 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Plavsic Mark sold about $80.2K of AURA on Feb 17, 2026; 4 other insiders sold within 30 days and 94 funds added in the latest 13F quarter.
63 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 58 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$39.1M over 180 days
-$39.0M of it by a 10%+ holder
below 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
94 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$39.1M repurchased, FY to 2026-06-30
more than 52% of Pharma & Biotech
Short interest
13.9% of the float short (float per yahoo 2026-10-26) · 9.2 days to cover · settled 2026-09-30
more than 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AURA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+10.9%12M
-13%+11%+34%+57%2025-102025-122026-022026-042026-062026-082026-10 2026-05-07 · Matrix Capital Management Company, LP sold $39.0M2026-02-17 · de los Pinos Elisabet sold $241.1K2026-02-17 · Hopkins Janet Jill sold $103.2K2025-11-17 · Hopkins Janet Jill sold $92.7K2026-04-16 · Kilroy Conor sold $82.4K2026-06-16 · Gibney Anthony S sold $82.3K2026-01-20 · de los Pinos Elisabet sold $82.3K2026-02-17 · Plavsic Mark sold $80.2K2026-02-17 · Kilroy Conor sold $61.0K2025-10-29 · de los Pinos Elisabet sold $57.5K2026-02-17 · Elazzouzi Amy sold $43.3K2026-01-20 · Elazzouzi Amy sold $7.7K2025-10-29 · Elazzouzi Amy sold $5.7K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AURA: institutional holders (13F)

13F holdings, latest reported quarter
TCG Crossover Management, LLC
9,533,333 sh
$67.7M
MONTANOVA CAPITAL, LLC
7,206,217 sh
$51.2M
Frazier Life Sciences Management, L.P.
7,100,000 sh
$50.4M
Nantahala Capital Management, LLC
5,902,060 sh
$41.9M
Long Focus Capital Management, LLC
5,119,582 sh
$36.3M

Congress trades in AURA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AURA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

AURA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$339.9K position · as of 2026-07-31
0.7%
AltShares Event-Driven ETF
$78.4K position · as of 2026-05-31
0.6%
Water Island Event-Driven Fund
$313.7K position · as of 2026-05-31
0.6%
Franklin Biotechnology Discovery Fund
$5.4M position · as of 2026-07-31
0.5%
iShares Micro-Cap ETF
$1.1M position · as of 2026-06-30
0.1%
VIP Disciplined Small Cap Portfolio
$373.2K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 2
1 active
1
Phase 3
1 active
4
Not applicable
3 active
1
Multi-phase
0 active
What changed recently
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (Co
2026-10-16 · Recruiting → Active Not Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $39.1M sold by insiders over 180 days, 94 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AURA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$103.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-53.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-47.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-53.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-15.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$112.8M-$96.1M-$85.0M-$60.3M
Net income-$106.2M-$86.9M-$76.4M-$58.8M
EPS (diluted)-1.76-1.75-1.93-1.96
Operating cash flow-$84.7M-$79.8M-$63.8M-$54.6M
Cash$59.5M$31.7M$41.1M$121.6M
SEC XBRL, fiscal years, as known on 2026-10-28

AURA Stock Sonar score 4/7 axes

Find similar shapesCompare

AURA ranks highest on institutional and government (66th percentile) and profitability (48th), and lowest on insider conviction (3rd), among Pharma & Biotech peers.

Profitability
48
Inputs
  • Return on equity-53.5% · 51 pct, sector of 545
  • Return on assets-47.4% · 46 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-53.3% · 47 pct, sector of 576
Insider conviction
3
Inputs
  • Net Form 4 buying (codes P and S), 180d-$39.1M · 5 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
66
Inputs
  • Funds adding, latest quarter94 · 66 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
27
Inputs
  • Short interest, % of float+13.9% · 27 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AURA filings, in plain words

Are Aura Biosciences insiders buying or selling AURA?

In the 180 days to 2026-10-28, Aura Biosciences insiders were net sellers, a net $39.1M across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Aura Biosciences insiders were net sellers of AURA, a net $39.1M across purchases and sales reported on Form 4 by 2 sellers. Most of that figure, $39.0M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies